Seventy seven of 304 and 48 of 201 node/metrics tested in studies one and two respectively distinguished FLT3-ITD from FLT3-WT AML patient samples with an AUC of ROC ≥0.6 and p≤0.05 (Tables S3, S4). Here, FLT3 is linked to acute myeloid leukemia.